SCHEMBL4717191

SCHEMBL4717191

NC(=O)N(CCOc1cc[c]cc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.42
MMP2 P08253 1/20 0.40
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
LTA4H P09960 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ESR1 P03372 1/20 0.36
ADRA2C P18825 1/20 0.36
ALDH1A1 P00352 3/20 0.36
ALOX5 P09917 1/20 0.36
USP2 O75604 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076343 0.77 KDM4E (0.50) PARP10KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL15227090 0.77 LTA4H (0.42) KDM4EMEN1KMT2ASMN1; SMN2PPARG
SCHEMBL5457872 0.74 MMP2 (0.42) PARP10MMP2MEN1KMT2AHSD17B10
SCHEMBL11505280 0.72 LTA4H (0.44) KDM4EMEN1KMT2APPARGLTA4H
SCHEMBL16278131 0.72 MLYCD (0.34) MEN1KMT2ASMN1; SMN2CYP3A4CYP2C9
SCHEMBL1990599 0.71 ADRA2C (0.50) MEN1KMT2ASMN1; SMN2CYP3A4CYP2C9
SCHEMBL5742511 0.71 ADRA2C (0.54) MEN1KMT2ASMN1; SMN2POLBCYP3A4
SCHEMBL4797271 0.71 NPC1 (0.50) MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL11427733 0.71 ALDH1A1 (0.50) KDM4EMEN1KMT2ASMN1; SMN2POLB
SCHEMBL28462432 0.70 THRB (0.39) CYP3A4ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689393-A4 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-12-17 EP disclosed
US-20070123561-A1 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors LEE DENNIS 2007-05-31 US disclosed
EP-1689393-A2 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2006-08-16 EP disclosed
WO-2005037198-A2 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123561-A1 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors TNK2, CDC42BPB, CDC42BPA PARP10 747/4885MMP2 2362/4885KDM4E 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.